Table 3.

 Differences in outcome between screening and control participants at 3-6 months* and 12-15 months†. Values are means (standard deviations) unless stated otherwise

Time	Control, non-screening	Screening group (attenders and non-attenders)	Difference‡ (95% CI), P value§
Self-reported health:
3-6 months	3.14 (0.80), n=443	3.13 (0.88), n=3211	0.02 (−0.13 to 0.18), 0.78
12-15 months	3.21 (0.81), n=383	3.15 (0.87), n=3093	−0.03 (−0.20 to 0.13), 0.70
State anxiety:
3-6 months	31.8 (11.4), n=358	33.5 (12.0), n=2504	1.51 (−0.17 to 3.20), 0.10
12-15 months	32.8 (11.8), n=304	33.5 (12.2), n=2377	0.57 (−1.11 to 2.24), 0.52
HADS anxiety:
3-6 months	5.97 (3.86), n=442	5.91 (3.89), n=3159	−0.12 (−0.55 to 0.32), 0.61
12-15 months	5.81 (3.87), n=377	5.85 (3.87), n=3034	−0.01 (−0.47 to 0.45), 0.98
HADS depression:
3-6 months	4.18 (3.38), n=444	4.24 (3.40), n=3177	0.01 (−0.51 to 0.54), 0.96
12-15 months	4.03 (3.35), n=378	4.28 (3.40), n=3049	0.22 (−0.31 to 0.74), 0.44
Worry about diabetes:
3-6 months	7.87 (2.35), n=428	7.79 (2.15), n=3041	−0.11 (−0.42 to 0.19), 0.48
12-15 months	8.08 (2.30), n=365	7.75 (2.21), n=2889	−0.33 (−0.67 to 0.01), 0.08

HADS=hospital anxiety and depression scale.

*Time since initial or scheduled (random blood glucose) test for screening group, 3-6 months since first contact or equivalent for control group.

†Time since initial or scheduled (random blood glucose) test for screening group, 12-15 months since first contact or equivalent for control group.

‡Screening group minus control group.

§Adjusted for age and comorbidity (use of antihypertensives).